Business UpdateOct 20, 2026, 08:02 AM
Vera Therapeutics Announces Upcoming Investor Webcasts for Clinical Trial Results and Q3 Financials
AI Summary
Vera Therapeutics announced two upcoming investor webcasts. The first, on October 22, will discuss the final efficacy results of the ORIGIN 3 clinical trial for TRUTAKNA™ (atacicept-vymj) in IgA nephropathy (IgAN), presented at ASN Kidney Week 2026. The second webcast, on November 5, will cover the company's third quarter 2026 financial results and business updates. TRUTAKNA is approved to reduce proteinuria in adults with IgAN at risk for disease progression.
Key Highlights
- Vera Therapeutics to host investor webcasts on Oct 22 (ORIGIN 3 results) and Nov 5 (Q3 2026 financials).
- ORIGIN 3 final efficacy results for TRUTAKNA™ (atacicept-vymj) to be presented at ASN Kidney Week 2026.
- TRUTAKNA is indicated to reduce proteinuria in adults with primary IgA nephropathy (IgAN).
- TRUTAKNA TRU SUPPORT™ patient program offers insurance and financial assistance.
- IgAN is a leading cause of chronic kidney disease and kidney failure worldwide.
Price Impact
More from VERA